Showing 4621-4630 of 5015 results for "".
- Is Pregnancy-Associated Melanoma More Lethal? Study Says Yeshttps://practicaldermatology.com/news/is-pregnancy-associated-melanoma-more-lethal-study-says-yes/2458744/Women who develop melanoma during their pregnancy or within one year of it are more likely to die from the disease, a new study suggests. Specifically, women diagnosed with malignant melanoma during their pregnancy or within one year of giving birth were 5.1-times as likely to die, 6.9-ti
- Indoor Tanning Linked to Teen Substance Abusehttps://practicaldermatology.com/news/indoor-tanning-linked-to-teen-substance-abuse/2458742/New research links teen indoor tanning with substance abuse. In a study of Colorado high school students, teens who took steroids were among the most likely to use tanning beds, especially adolescent boys. Alcohol consumption in the past 30 days, marijuana use and lifetime use of select i
- Psoriasis Treatment Update: Rx Enstilar® Is Herehttps://practicaldermatology.com/news/psoriasis-treatment-update-rx-enstilaris-is-here/2458747/Enstilar®, the recently approved plaque psoriasis foam, is now available in pharmacies by prescription. Manufactured by LEO Pharma, Inc., Enstilar
- Concern About Zika Virus in US Set to Escalatehttps://practicaldermatology.com/news/concern-about-zika-virus-in-us-set-to-escalate/2458751/U.S dermatologists may start to receive calls from patients who are concerned about infection with Zika virus – particularly pregnant ones. Zika is now spreading rapidly across Latin America and the Caribbean. So far, one case has been identified in Houston, but the possibility
- New Blood Test Gets Leg Up On Advanced Melanomahttps://practicaldermatology.com/news/new-blood-test-gets-leg-up-on-advanced-melanoma/2458756/A blood test that monitors blood levels of DNA fragments from dead cancer cells may be better at tracking progression of metastatic melanoma than the current standard blood test. The standard test measures blood levels of the enzyme lactate dehydrogenase (LDH), which tend t
- Galderma Laboratories, L.P. Appoints Miles Harrison as Leader of U.S. and Canadahttps://practicaldermatology.com/news/galderma-laboratories-lp-appoints-miles-harrison-as-leader-of-us-and-canada/2458762/Galderma promoted Miles Harrison to President and General Manager of Galderma Laboratories, L.P. leading the US and Canada teams. Miles Harrison joined Galderma US in 2014 as the Vice President
- Paratek To Complete Omadacycline Phase 3 Skin Trial Earlier Than Expectedhttps://practicaldermatology.com/news/paratek-completes-enrollment-for-omadacycline-phase-3-skin-trial-earlier-than-expected/2458767/Paratek Pharmaceuticals, Inc. may report top-line data from its ongoing pivotal Phase 3 clinical trial evaluating omadacycline for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSS
- MELA Sciences Changing Name to STRATA Skin Sciences to Reflect Broader Dermatology Commitmenthttps://practicaldermatology.com/news/mela-sciences-changing-name-to-strata-skin-sciences-to-reflect-broader-dermatology-commitment/2458771/MELA Sciences, Inc. will be changing its corporate name to STRATA Skin Sciences, Inc. effective Tuesday, January 5, 2016 and it will trade under the symbol “SSKN” on the Nasdaq Stock Market. Michael R. Stewart, President and Chief Executive Officer stated: “Our June 2015
- FDA Approves Expanded Indication for Merck's Keytruda for Treatment of Advanced Melanomahttps://practicaldermatology.com/news/fda-approves-expanded-indication-for-mercks-keytruda-for-treatment-of-advanced-melanoma/2458773/The FDA has approved an expanded indication for Merck’s Keytruda® (pembrolizumab), an anti-PD-1 (programmed death receptor-1) therapy, to include the first-line treatment of patients with unresectable or metastatic melanoma. This approval marks the second FDA-approved indicat
- Oculus Innovative Sciences Receives FDA Clearance for Microcyn-Based SebDerm Gelhttps://practicaldermatology.com/news/oculus-innovative-sciences-receives-fda-clearance-for-microcyn-based-sebderm-gel/2458780/Oculus Innovative Sciences, Inc. received a new 510(k) clearance from the FDA for the company’s new Microcyn®-based SebDerm Gel. As a prescription product, SebDerm Gel is intended to manage and relieve the burning, itching, erythema, scaling, and pain experienced with seborrh